Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Lineage Cell Therapeutics Inc’s stock clocked out at $0.51, up 1.30% from its previous closing price of $0.50. In other words, the price has increased by $1.30 from its previous closing price. On the day, 6.4 million shares were traded. LCTX stock price reached its highest trading level at $0.5418 during the session, while it also had its lowest trading level at $0.4912.
Ratios:
To gain a deeper understanding of LCTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 3.65. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on August 20, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On November 02, 2022, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.
On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on June 14, 2022, with a $4 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 27 ’25 when BROADWOOD PARTNERS, L.P. bought 7,894,737 shares for $0.76 per share. The transaction valued at 6,000,000 led to the insider holds 49,560,992 shares of the business.
Howe Jill Ann bought 15,000 shares of LCTX for $8,850 on Nov 26 ’24. The Chief Financial Officer now owns 25,500 shares after completing the transaction at $0.59 per share. On Nov 26 ’24, another insider, Samuel George A. III, who serves as the General Counsel of the company, bought 15,000 shares for $0.60 each. As a result, the insider paid 9,000 and bolstered with 22,184 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 115662312 and an Enterprise Value of 69002464. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.17 while its Price-to-Book (P/B) ratio in mrq is 1.42. Its current Enterprise Value per Revenue stands at 7.264 whereas that against EBITDA is -3.306.
Stock Price History:
The Beta on a monthly basis for LCTX is 1.29, which has changed by -0.6015625 over the last 52 weeks, in comparison to a change of 0.086116076 over the same period for the S&P500. Over the past 52 weeks, LCTX has reached a high of $1.61, while it has fallen to a 52-week low of $0.48. The 50-Day Moving Average of the stock is -15.48%, while the 200-Day Moving Average is calculated to be -34.84%.
Shares Statistics:
It appears that LCTX traded 1.77M shares on average per day over the past three months and 2328100 shares per day over the past ten days. A total of 228.36M shares are outstanding, with a floating share count of 227.36M. Insiders hold about 0.44% of the company’s shares, while institutions hold 51.10% stake in the company. Shares short for LCTX as of 1740700800 were 22027996 with a Short Ratio of 12.42, compared to 1738281600 on 21298495. Therefore, it implies a Short% of Shares Outstanding of 22027996 and a Short% of Float of 15.290000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
